Healthcare
Pulmatrix, Inc.(PULM)
Live Price
Offline$1.42
+3.28% today
1Y Change
-80.03%
Window
Jun 23, 2025 โ Jun 9, 2026
- Market Cap
- โ
- Revenue Growth
- -100.0%
- EPS Growth
- +46.2%
- Dividend Yield
- 0.0%
Coverage: 243 bars ยท Jun 23, 2025 โ Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pulmatrix, Inc. (PULM) is a Healthcare stock with listed on NASDAQ. The stock last traded around $1.42 and down 80.0% across the available one-year price window (Jun 23, 2025 โ Jun 9, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +46.2%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +46.2%, free cash flow +51.1% with operating margin 0.0% and ROIC -135.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PULM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +46.2%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -7.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +0.0% | +0.0% | โ |
2026 Feb 26, 2026 | โ | +2.7% | -26.5% | -48.1% |
2025 Oct 16, 2025 | โ | +3.7% | +4.5% | +5.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PULM
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PULM Max Drawdown
-83.12%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PULM and SPY.
Company Overview
Pulmatrix, Inc.
NASDAQ Capital Market
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
- Leadership
- Peter Ludlum
- IPO Date
- Mar 21, 2014
- Employees
- 2
- Street Address
- 99 Hayden Avenue
- Mailing
- Lexington, MA, 02421
- Region
- Lexington, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 357 2333
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.2
Growth
- Revenue
- -100.0%
- EPS
- +46.2%
- Free Cash Flow
- +51.1%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -97.0%
- ROIC
- -135.7%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 12.55
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.